Enter your search terms:
Top

Strong pipeline of products with therapeutic benefits

Aquestive is the undisputed leader in developing and delivering medications via film through our PharmFilm technology.  Building on our success, we now have a robust CNS and complex molecule portfolio.  We continuously strive to identify therapeutic areas where our proprietary technologies can help improve patient outcomes.

Program Molecule Indication Formulation Pre-Clinical Phase 1 Phase 2 Phase 3 Filed Marketed
CNS Programs
AQST-120 (Sympazan™) clobazam Lennox-Gastaut syndrome
 
AQST-203 diazepam* Acute Repetitive Seizures
 
AQST-117 riluzole* ALS
 
Complex Molecule Programs
AQST-108 epinephrine* Anaphylaxis
 
AQST-305 octreotide* Acromegaly / Carcinoid Syndrome
 
Partnered Programs
Suboxone (Partner: Indivior) buprenorphine / naloxone Opioid Dependence
 
Zuplenz (Partner: Midatech) ondansetron CINV / PINV
 
APL-130277 (Partner: Sunovion) apomorphine* Parkinson’s Disease
 
AQST-119 tadalafil* Erectile Dysfunction / BPH
 
*Assets are currently in development. Final indication is subject to the completion of trials; assessment of clinical and safety data; plus the filing, review, and evaluation by FDA and regulatory authorities.
Current as of October 2018

CNS Programs

AQST-120

+

Molecule: clobazam

Indication: Lennox-Gestaut syndrome

Phase: filed

AQST-203

+

Molecule: diazepam*

Indication: acute repetitive seizures

Phase: 3

AQST-117

+

Molecule: riluzole*

Indication: ALS

Phase: 3

Complex Molecule Programs

AQST-108

+

Molecule: epinephrine*

Indication: Anaphalaxis

Phase: 1

AQST-305

+

Molecule: octreotide*

Indication: Acromegaly / Carcinoid Syndrome

Phase: 1

Partnered Programs

Suboxone

+

Molecule: buprenorphine / naloxone

Indication: Opioid Dependence

Phase: marketed

Partner: Indivior

Zuplenz

+

Molecule: ondansetron

Indication: CINV / PINV

Phase: filed

Partner: Midatech

APL-130277

+

Molecule: apomorphine*

Indication: Parkinson’s Disease

Phase: 3

Partner: Sunovion

AQST-119

+

Molecule: tadalafil*

Indication: Erectile Dysfunction / BPH

Phase: filed

Partner: Actively pursuing partnerships

*Assets are currently in development. Final indication is subject to the completion of trials; assessment of clinical and safety data; plus the filing, review, and evaluation by FDA and regulatory authorities.

 

Current as of October 2018

Latest comments

Sorry, the comment form is closed at this time.